Nicox First Half 2020 Financial Results and Business Update

nicox sa
Interim Consolidated statement of Comprehensive Income(1) Includes €4.7 million of non-recurrent revenue received from our partners Ocumension and Eyevance
(2) Includes €6.9 million of expenses without cash impact related to the impairment of VISUfarma assets sold in July 2020
(3) Non-cash income tax for deferred tax assets recognized by our U.S subsidiary nicox sa
Interim consolidated statement of financial position(1) VISUfarma’s assets divested in July 2020
(2) Includes an amount of €14 million over a payment of €15 million received from Ocumension Therapeutics following the execution in March 2020 of the amendment to the licensing agreement for NCX 470 in China AttachmentEN_H1 2020results_20200910_F2_F
